3TC approved
Tags: HIV infections -- Treatment
Related Articles
- Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication. Alcami, Jose; Coiras, Mayte; Lopez-Huertas, Maria Rosa; Perez-Olmeda, Mayte // Retrovirology;2010 Supplement 1, Vol. 7, p1
An abstract of the article "Molecular Mechanisms Involved in HIV Latency and Implications for HIV Treatment and Eradication," Jose Alcami, Mayte Coiras, Maria Rosa Lopez-Huertas and Mayte Perez-Olmedaby is presented.
- Treatments for persistent HIV infection: the road ahead. Margolis, David M. // Retrovirology;2010 Supplement 1, Vol. 7, p1
An abstract of the article "Treatments for Persistent HIV Infection: The Road Ahead," by David M. Margolis is presented.
- Effect of range of spread of CD4 count and RNA level on the efficacy of HIV treatments. Towfic, George; Kettoola, Samira // Retrovirology;2010 Supplement 1, Vol. 7, p1
An abstract of the article "Effect of Range of Spread of CD4 Count and RNA Level on the Efficacy of HIV Treatments," by George Towfic and Samira Kettoola is presented.
- Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia. Bourinbaiar, Aldar; Orlovsky, Vladimir; Jirathitikal, Vichai; Metadilogkul, Orapun; Dmitry, Popov // Retrovirology;2010 Supplement 1, Vol. 7, p1
An abstract of the article "Pilot Trial of Oral Therapeutic HIV Vaccine, V-1 Immunitor, on HIV and HIV/HCV Patients in Russia," by Aldar Bourinbaiar, Vladimir Orlovsky, Vichai Jirathitikal, Orapun Metadilogkul and Popov Dmitry is presented.
- HAART therapy doubles in quarter. // Medical Marketing & Media;Nov97, Vol. 32 Issue 11, p26
Reports on the increase in the number of newly diagnosed HIV patients being treated with the Highly Active Anti-Retroviral Therapy (HAART) in the second quarter of 1997. Data from IMS America.
- Interpreting Treatment Differences When Patients Drop Out of a Clinical Trial. Lindsey, Jane C.; McGrath, Nuala M. // AIDS Patient Care & STDs;Apr98, Vol. 12 Issue 4, p275
Presents information on how drugs are selected for the treatment of the human immunodeficiency virus (HIV) disease in patients using a clinical trial. How the drugs are judged; Identification of the Pediatric Aids Clinical Trials Group (PACTG) Protocol 051; What happens when a patient drop out...
- ABACAVIR (1592) WITH PROTEASE INHIBITORS IN POTENT ANTIRETROVIRAL ACTIVITY. // AIDS Patient Care & STDs;Apr98, Vol. 12 Issue 4, p315
Presents information on a study regarding combining the investigational anti-human immunodeficiency virus (HIV) drug abacavir with one of five protease inhibitors. Identification of the five protease inhibitors; Methodology used in the study; How the drugs perform when they are combined.
- CANADA PUBLISHES GUIDELINES. // AIDS Patient Care & STDs;Jul98, Vol. 12 Issue 7, p513
Reports on the publication of guidelines pertaining to human immunodeficiency virus, by the Canadian government. Details on the two reports; Contact point for information.
- TWO-DRUG REGIMEN MAY BE EFFECTIVE. // AIDS Patient Care & STDs;Aug98, Vol. 12 Issue 8, p646
Focuses on a study which was published in the May 7, 1998 issue of `AIDS' journal, which reported on a two-drug antiretroviral regimen that appears to be effective in suppressing the human immunodeficiency virus (HIV). Names of drugs which were given to five patients with HIV infection; Who...
- Daily Dosing of Highly Active Antiretroviral Therapy. Rosenbach, Keith A.; Allison, Robert; Nadler, Jeffrey P. // Clinical Infectious Diseases;3/1/2002, Vol. 34 Issue 5, p686
Reviews a strategy for developing medications and regimens for the management of HIV infection that can be taken once per day. Goal of the strategy; Comparison of regimen with two or three times daily dosing with a regimen with once-daily dosing; Findings from studies of regimens with...
